Cadila Pharma wins best launch of the year award for Esiloc. It is the only anti-ulcerant that offers both affordability and a 17-hour gastric acid control (as against 9-14 hours of acid control by much more expensive alternatives).
Ahmedabad: Ahmedabad-based Cadila Pharmaceuticals, one of the oldest and largest privately-held pharma companies in the country, has been named as the second runner up for the “Best Launch of the Year” award for the launch of Esiloc, its brand of tablets used for the treatment of hyperacidity & drug-induced gastritis. Cadila Pharmaceuticals was bestowed the honour at the Pronto Consult Consumer Awards, which are aimed at recognising excellence in healthcare.
“We are thrilled to receive the Pronto Consult Consumer Award for the best launch of the year for Esiloc. Esiloc was truly a breakthrough product and is the most prescribed esomeprazole brand by general practitioners and number six overall just within 18 months of its launch. We are thankful to the doctors and patients for their trust in us,” said Abhinav Sharma, Marketing Head, Cadila Pharmaceuticals.
Cadila Pharmaceuticals launched Esiloc in July 2020, positioning it as the only anti-ulcerant that offers both affordability and a 17-hour gastric acid control (as against 9-14 hours of acid control by much more expensive alternatives). It targeted the market by converting the bottom of the pyramid subscribers through the first mover advantage.
Also read Cadila launches Esiloc™ tablets for hyperacidity
Esiloc was launched at the biggest doctor engagement webinar involving more than 12,000 doctors across the country. The company also attempted to create a Limca Book Record in the process in partnership with NIMA, besides engaging with doctors in the metros and 70 top cities through various initiatives.
It reached out to doctors in rural areas through various engagement initiatives and also engaged with customers directly in states having high usage of anti-ulcerants by communicating with them in the local/regional languages. Cadila Pharmaceuticals also enhanced Esiloc’s brand visibility during fieldwork. Special webinars were also organised for stockists, and the power of digital media was used to reach uncovered areas/customers. The engagement initiatives with doctors and patients alike have played a vital role in making Esiloc the preferred anti-ulcerant tablet.
Esiloc is 50% more economical than alternatives making it a superior yet affordable choice to treat hyperacidity and drug-induced gastritis. It is available in 20 mg and 40 mg tablets.
